Kalshi drug trial prediction markets raise ethical concerns among attorneys

Kalshi Inc.'s opening of prediction markets for clinical drug trials has raised compliance concerns for attorneys, including the risk of what one source called 'a moral hazard.' The markets allow traders to bet on the outcomes of pharmaceutical trials, creating potential conflicts with research integrity and patient welfare. Attorneys flagged ethical qualms about whether financial incentives could influence trial conduct or disclosure.

Creates a new regulatory gray area for event contracts tied to biomedical research, potentially inviting CFTC scrutiny or state AG action if patient harm or data manipulation is linked to trading incentives.